<?xml version='1.0' encoding='utf-8'?>
<document id="22404663"><sentence text="Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate."><entity charOffset="46-56" id="DDI-PubMed.22404663.s1.e0" text="lacosamide" /><entity charOffset="58-68" id="DDI-PubMed.22404663.s1.e1" text="retigabine" /><entity charOffset="73-96" id="DDI-PubMed.22404663.s1.e2" text="eslicarbazepine acetate" /><pair ddi="false" e1="DDI-PubMed.22404663.s1.e0" e2="DDI-PubMed.22404663.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22404663.s1.e0" e2="DDI-PubMed.22404663.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22404663.s1.e0" e2="DDI-PubMed.22404663.s1.e2" /><pair ddi="false" e1="DDI-PubMed.22404663.s1.e1" e2="DDI-PubMed.22404663.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22404663.s1.e1" e2="DDI-PubMed.22404663.s1.e2" /></sentence><sentence text="The search for new, more effective antiepileptic drugs (AEDs) continues" /><sentence text=" The three most recently approved drugs, the so-called third-generation AEDs, include lacosamide, retigabine and eslicarbazepine acetate and are licensed as adjunctive treatment of partial epilepsy in adults"><entity charOffset="86-96" id="DDI-PubMed.22404663.s3.e0" text="lacosamide" /><entity charOffset="98-108" id="DDI-PubMed.22404663.s3.e1" text="retigabine" /><entity charOffset="113-136" id="DDI-PubMed.22404663.s3.e2" text="eslicarbazepine acetate" /><pair ddi="false" e1="DDI-PubMed.22404663.s3.e0" e2="DDI-PubMed.22404663.s3.e0" /><pair ddi="false" e1="DDI-PubMed.22404663.s3.e0" e2="DDI-PubMed.22404663.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22404663.s3.e0" e2="DDI-PubMed.22404663.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22404663.s3.e1" e2="DDI-PubMed.22404663.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22404663.s3.e1" e2="DDI-PubMed.22404663.s3.e2" /></sentence><sentence text="" /><sentence text="For the above three AEDs, their mechanisms of action, pharmacokinetic characteristics, drug-drug interactions, pharmacotherapeutics, dose and administration and therapeutic drug monitoring are reviewed in this paper" /><sentence text="" /><sentence text="Lacosamide and retigabine act through novel mechanisms, while eslicarbazepine acetate, a pro-drug for eslicarbazepine, acts in a similar manner to several other AEDs"><entity charOffset="0-10" id="DDI-PubMed.22404663.s7.e0" text="Lacosamide" /><entity charOffset="15-25" id="DDI-PubMed.22404663.s7.e1" text="retigabine" /><entity charOffset="62-85" id="DDI-PubMed.22404663.s7.e2" text="eslicarbazepine acetate" /><entity charOffset="102-117" id="DDI-PubMed.22404663.s7.e3" text="eslicarbazepine" /><pair ddi="false" e1="DDI-PubMed.22404663.s7.e0" e2="DDI-PubMed.22404663.s7.e0" /><pair ddi="false" e1="DDI-PubMed.22404663.s7.e0" e2="DDI-PubMed.22404663.s7.e1" /><pair ddi="false" e1="DDI-PubMed.22404663.s7.e0" e2="DDI-PubMed.22404663.s7.e2" /><pair ddi="false" e1="DDI-PubMed.22404663.s7.e0" e2="DDI-PubMed.22404663.s7.e3" /><pair ddi="false" e1="DDI-PubMed.22404663.s7.e1" e2="DDI-PubMed.22404663.s7.e1" /><pair ddi="false" e1="DDI-PubMed.22404663.s7.e1" e2="DDI-PubMed.22404663.s7.e2" /><pair ddi="false" e1="DDI-PubMed.22404663.s7.e1" e2="DDI-PubMed.22404663.s7.e3" /><pair ddi="false" e1="DDI-PubMed.22404663.s7.e2" e2="DDI-PubMed.22404663.s7.e2" /><pair ddi="false" e1="DDI-PubMed.22404663.s7.e2" e2="DDI-PubMed.22404663.s7.e3" /></sentence><sentence text=" All three AEDs are associated with linear pharmacokinetic and rapid absorption and undergo metabolism" /><sentence text=" Their drug-drug interaction profile is low (lacosamide and retigabine) to modest (eslicarbazepine) in propensity"><entity charOffset="45-55" id="DDI-PubMed.22404663.s9.e0" text="lacosamide" /><entity charOffset="60-70" id="DDI-PubMed.22404663.s9.e1" text="retigabine" /><entity charOffset="83-98" id="DDI-PubMed.22404663.s9.e2" text="eslicarbazepine" /><pair ddi="false" e1="DDI-PubMed.22404663.s9.e0" e2="DDI-PubMed.22404663.s9.e0" /><pair ddi="false" e1="DDI-PubMed.22404663.s9.e0" e2="DDI-PubMed.22404663.s9.e1" /><pair ddi="false" e1="DDI-PubMed.22404663.s9.e0" e2="DDI-PubMed.22404663.s9.e2" /><pair ddi="false" e1="DDI-PubMed.22404663.s9.e1" e2="DDI-PubMed.22404663.s9.e1" /><pair ddi="false" e1="DDI-PubMed.22404663.s9.e1" e2="DDI-PubMed.22404663.s9.e2" /></sentence><sentence text=" At the highest approved doses for the three AEDs, responder rates were similar" /><sentence text=" The most commonly observed adverse effects compared with placebo were dizziness, headache, diplopia and nausea for lacosamide; dizziness, somnolence and fatigue for retigabine and dizziness and somnolence for eslicarbazepine acetate"><entity charOffset="116-126" id="DDI-PubMed.22404663.s11.e0" text="lacosamide" /><entity charOffset="166-176" id="DDI-PubMed.22404663.s11.e1" text="retigabine" /><entity charOffset="210-233" id="DDI-PubMed.22404663.s11.e2" text="eslicarbazepine acetate" /><pair ddi="false" e1="DDI-PubMed.22404663.s11.e0" e2="DDI-PubMed.22404663.s11.e0" /><pair ddi="false" e1="DDI-PubMed.22404663.s11.e0" e2="DDI-PubMed.22404663.s11.e1" /><pair ddi="false" e1="DDI-PubMed.22404663.s11.e0" e2="DDI-PubMed.22404663.s11.e2" /><pair ddi="false" e1="DDI-PubMed.22404663.s11.e1" e2="DDI-PubMed.22404663.s11.e1" /><pair ddi="false" e1="DDI-PubMed.22404663.s11.e1" e2="DDI-PubMed.22404663.s11.e2" /></sentence><sentence text=" The precise role that these new AEDs will have in the treatment of epilepsy and whether they will make a significant impact on the prognosis of intractable epilepsy is not yet known and will have to await further clinical experience" /><sentence text="" /></document>